CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026

Data ReadoutleronlimabTAS-102bevacizumabNeutral

AI Analysis

Summary

CytoDyn announced it will present updated Phase 2 CLOVER study data evaluating leronlimab in combination with TAS-102 and bevacizumab for previously treated metastatic colorectal cancer at ESMO Congress 2026 on October 23-27, 2026 in Madrid.

Clinical Trial Data

Phase

Phase 2

NCT ID

NCT06699836

Outcome Details

Updated Phase 2 CLOVER study data presentation at ESMO Congress 2026

Importance:5/10

Sentiment:

0.20

leronlimabCCR5 receptoroncologycolorectal cancertriple-negative breast cancerCLOVER studyESMO Congress 2026combination therapy

Related Companies

$CYDY

Read the original article

Published by GlobeNewswire Clinical Studies on October 8, 2026 12:30 PM

Read Original